Skip to content
Biotechnology, Business Company News

Australian reproductive biotechnology company Memphasys enhances board with appointment of Michael Atkins as Non-Executive Director

Chapter One Advisors 2 mins read
Michael Atkins

Australian-based reproductive biotechnology company, Memphasys Limited (ASX: MEM), has enhanced its board with the appointment of successful corporate executive Michael Atkins as an independent non-executive director, effective immediately.

Since 1987 Michael has been involved with the formation of, and capital raising for, and management of, many listed companies on the ASX, both as a Chairman/Director and as a corporate advisor.

Importantly for Memphasys, he has direct experience working in many countries throughout Asia, North America, Africa, and Europe.

Mr Atkins was, until November 2021, a Senior Advisor to international stockbroker Canaccord Genuity in Australia. Prior to that he spent more than 16 years in senior corporate advisory roles with several Australian stockbroking roles, including 10 years as Director – Corporate Finance at Paterson Securities. Mr Atkins is currently the Chair of Castle Minerals Limited and non-executive Director of SRG Global Limited, both ASX listed.

Commenting on the appointment, Non-Executive Chairman Robert Cooke, said, “Michael has a proven track record of achieving strong shareholder value and returns for the companies he has led, and we are pleased to have attracted someone with his experience to the board.

“As we continue to advance our commercialistion activities across our portfolio of assets we think this experience will be of immense benefit to the board and executive of Memphasys.”

Mr Atkins added, “I have been a shareholder of Memphasys for many years and I welcome the opportunity to work with the board and executive as they continue to execute the company’s commercialisation plans.

“I genuinely believe the commercial opportunity for Memphasys, across its portfolio, will rapidly advance in 2024 (and beyond) and am excited to play a role in that activity.”

Mr Atkins is a Fellow of the Australian Institute of Company Directors and has a Bachelor of Commerce degree from the University of Western Australia.

About us:

About Memphasys


Memphasys Limited (ASX: MEM) specialises in reproductive biotechnology for high value commercial applications. Reproductive biotechnology products in development include medical devices, in vitro diagnostics, and new proprietary media. The Company’s patented bio-separation technology, utilised by the Company’s most advanced product, the Felix™ System device, combines electrophoresis with proprietary size exclusion membranes to separate the most viable sperm cells for human artificial reproduction.




The Felix™ System is a registered trademark of Memphasys Limited. All rights reserved.

Contact details:

David Tasker
T: +61 433 112 936


More from this category

  • Business Company News, Human Resources
  • 24/04/2024
  • 15:55

LinkedIn reveals Australia’s Top Companies for career growth in 2024

LinkedIn has unveiled its 8th annual Top Companies List – a data-backed ranking of the 25 best employers to grow a career in Australia right now. Fuelled by unique LinkedIn data, the methodology looks at different aspects of career progression like how employees are getting promoted, adding new skills, gender diversity and more. This year’s list has seen Commonwealth Bank take out the top spot, with Canva making its debut at number nine – the first time the online design and visual communication platform has moved from the top startup companies list. Please note that the companies aren’t aware where…

  • Business Company News, Oil Mining Resources
  • 24/04/2024
  • 12:02

CIMIC increases ownership of Thiess to 60%

CIMIC Group has entered into an agreement with funds advised by Elliott Advisors (UK) Ltd (Elliott) regarding the acquisition by CIMIC of an additional…

  • Contains:
  • Business Company News
  • 23/04/2024
  • 07:19
Chartered Accountants ANZ

CA ANZ Media Release – Climate related reporting a huge financial burden for Group 3 firms

23 April 2024 CLIMATE REPORTING BILL A SIGNIFICANT COST FOR GROUP 3 BUSINESSES Almost 90 per cent of auditors who responded to a new survey from peak accounting body Chartered Accountants ANZ (CA ANZ) do not support the Government’s requirements to implement mandatory Climate Reporting and assurance on Group 3 Firms. Group 3 Firms include private companies, Not for Profits, or companies limited by guarantee. The survey was conducted by CA ANZ between 12 and 17 April 2024. Members that were surveyed included those involved with reporting and auditing work, work with SMP or NFP organisations, or have a direct…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.